Brenton Mar

As Head of Clinical Development, Brenton Mar oversees clinical strategy for Relay’s portfolio of innovative clinical trials in the oncology and rare disease space, including Relay’s first-in-class allosteric mutant selective PIK3CA inhibitor, RLY-2608. Brenton is a physician-scientist, a pediatric hematologist-oncologist by training, with over 20 years of research experience between academia and industry, with a career mission of translating genomic discoveries into new life changing therapies for patients.
Prior to Relay, Brenton was a vice-president of clinical development at Blueprint Medicines, where he led clinical efforts for the breakthrough designation and the FDA approval of the KIT D816V inhibitor, avapritinib (Ayvakit®), for advanced systemic mastocytosis. He also took several targeted therapeutics from investigational new drug (IND) to Proof of Concept (PoC) in lung cancer, including early stage EGFR inhibitors and the RET inhibitor, pralsetinib (Gavreto®).
Brenton holds an M.D. and Ph.D. in molecular genetics from the University of Illinois at Chicago. He completed pediatrics residency at the Children’s Hospital of New York and pediatric hematology-oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute.